A short report on highlights of world-wide development of RIX4414: a Latin American experience.
暂无分享,去创建一个
G. Ruiz-Palacios | B. Innis | A. Linhares | Y. Cervantes | J. Yarzábal | I. Pérez-Schael | B. De Vos | K. Hardt | B. Salinas | G. Vespa | S. C. Clemens | M. L. Guerrero
[1] T. Vesikari,et al. Efficacy of RIX4414 Live Attenuated Human Rotavirus Vaccine in Finnish Infants , 2004, The Pediatric infectious disease journal.
[2] R. Glass,et al. The future of rotavirus vaccines: a major setback leads to new opportunities , 2004, The Lancet.
[3] Mark A. Miller,et al. Global Illness and Deaths Caused by Rotavirus Disease in Children , 2003, Emerging infectious diseases.
[4] D. Matson,et al. Rotavirus-associated medical visits and hospitalizations in South America: a prospective study at three large sentinel hospitals , 2001, The Pediatric infectious disease journal.
[5] J. Bresee,et al. Rotavirus vaccines and vaccination in Latin America. , 2000, Revista panamericana de salud publica = Pan American journal of public health.
[6] R. Glass,et al. Rotavirus G and P types circulating in Brazil: characterization by RT-PCR, probe hybridization, and sequence analysis , 2005, Archives of Virology.
[7] T. Vesikari,et al. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. , 1990, Scandinavian journal of infectious diseases.